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Summary The hypothesis that serum concentrations of pituitary hormones, sex steroid hormones, or sex
hormone-binding globulin (SHBG) affect the occurrence ofprostatic cancer was tested in a consecutive sample
of 93 patients with newly diagnosed, untreated cancer and in 98 population controls of similar ages without
the disease.
Cases did not differ significantly from controls regarding serum levels of luteinising hormone (LH) or follicle
stimulating hormone (FSH). Remarkably close agreement was found for mean values of total testosterone
(15.8 nmol l-' in cases and 16.0 in controls), and free testosterone (0.295 and 0.293 nmol 1-', respectively),
with corresponding odds ratios for the highest vs lowest tertile of 1.0 (95% confidence interval 0.5-1.9) for
testosterone and 1.2 (95% confidence interval 0.6-2.4) for free testosterone. Similar close agreement between
cases and controls was found for serum concentrations of estradiol, androstenedione and SHBG, although the
mean estradiol level was non-significantly (P = 0.30) lower among cases. Changes secondary to the disease
were unlikely to have affected the results materially, since only LH and FSH were associated with stage of
disease and this relationship was weak.
Our findings suggest that further analyses of serum hormone levels at the time of diagnosis are unlikely to
improve our understanding of the etiology of prostatic cancer.
Sex steroid hormones are required for normal growth and
function of the prostate (Coffey & Isaacs, 1981). It has also
been proposed that they may be involved in the development
of prostatic cancer (Greenwald, 1982), and tumour tissue
often responds to hormonal manipulation (Huggins & Hod-
ges, 1941; DeVita et al., 1982), perhaps because of the
presence of hormone receptors (Barrack et al., 1983; Habib et
al., 1986). Moreover, prostatic tumours can be induced in the
rat by prolonged administration of testosterone (Noble,
1977).
Analytic epidemiologic studies on effects of hormones in
humans have mainly had a case-control design. In two in-
stances, steroid hormone levels were analysed in serum sam-
ples stored for a number of years before the disease was
manifested, using a nested case-control design (Nomura et
al., 1988; Barrett-Connor et al., 1990). In general, however,
serum samples were drawn at the time of diagnosis of the
cases (Harper et al., 1976; Bartsch et al., 1977a; Bartsch et
al., 1977b; Hammond et al., 1978; Ghanadian et al., 1979;
Habib, 1980; Jackson et al., 1980; Saroff et al., 1980;
Ahluwalia et al., 1981; Drafta et al., 1982; Hill et al., 1982;
H0isaeter et al., 1982; Meikle & Stanish, 1982; Zumoff et al.,
1982; Ranikko & Adlercreutz, 1983; Meikle et al., 1985;
Hulka et al., 1987; Hsing & Comstock, 1989). In general such
comparisons have given conflicting results. Plasma testo-
sterone levels in patients with prostatic cancer have been
reported to be both higher than (Ghanadian et al., 1979;
Jackson et al., 1980; Ahluwalia et al., 1981; Drafta et al.,
1982), similar to (Young & Kent, 1968; Harper et al., 1976;
Bartsch et al., 1977a; Bartsch et al., 1977b; Hammond et al.,
1978; Habib, 1980; H0isaeter et al., 1982; Ranikko & Adler-
creutz, 1983; Levell et al., 1985; Nomura et al., 1988; Hsing
& Comstock, 1989; Barrett-Connor et al., 1990) and lower
than (Jackson et al., 1980; Ahluwalia et al., 1981; Hill et al.,
1982; Meikle & Stanish, 1982; Zumoff et al., 1982; Levell et
al., 1985; Meikle et al., 1985) those in healthy controls.
Similarly, conflicting results have been reported for estradiol
(Harper et al., 1976; Bartsch et al., 1977a; Bartsch et al.,
1977b; Hammond et al., 1978; Jackson et al., 1980; Jacobi et
al., 1980; Ahluwalia et al., 1981; Drafta et al., 1982; Hill et
al., 1982; H0isaeter et al., 1982; Meikle & Stanish, 1982;
Ranikko & Adlercreutz, 1983; Hulka et al., 1987; Nomura et
al., 1988; Hsing & Comstock, 1989; Barrett-Connor et al.,
1990), androstenedione (Harper et al., 1976; Hammond et al.,
1978; Habib, 1980; Hill et al., 1982; Barrett-Connor et al.,
1990), and sex hormone-binding globulin (SHBG) (H0isaeter
et al., 1982; Ranikko & Adlercreutz, 1983; Hulka et al.,
1987).
The equivocal results obtained so far with regard to the
role of hormones in the etiology of prostatic cancer have
several reasons. They may be due to chance, to low statistical
power (i.e. small numbers of cases and controls), to
difficulties in selecting proper controls, or to changing hor-
mone levels as part of the disease process. Thus, available
data cannot reject or confirm the hypothesis that hormonal
mechanisms are important in the etiology of prostatic cancer
and that they are reflected in serum hormone levels at the
time of diagnosis.
The aim of this study was to compare the serum concen-
trations of pituitary hormones, steroid hormones and sex
hormone-binding globulin (SHBG) between patients with a




The patients and controls were participating in an ongoing,
population-based, case-control interview study. We decided
in advance to confine the analysis of hormones and SHBG in
the serum to the first 100 cases included and the same
number of controls. The study base consisted of all males
under the age of 80 years born in Sweden and living in one
county (Orebro). The source population comprised around
270,000 individuals in 1988 (The Cancer Registry, 1991). In
this population all males suspected of having prostatic cancer
are referred to either of the three hospitals in the county for
further diagnostic work-up and treatment.
Eligible for the study were all patients with a newly diag-
nosed, cytologically and/or histologically confirmed prostatic
cancer. Of the 100 patients included, 22 had a cancer first
detected at histopathologic examination of the surgical speci-
men removed at TUR (To); all others had palpable tumours
Correspondence: S.-O. Andersson, Department of Urology, Orebro
Medical Center Hospital, S-701 85 Orebro, Sweden.
Received 8 October 1992; and in revised form 21 January 1993.
'." Macmillan Press Ltd., 1993 Br. J. Cancer (1993), 68, 97-10298 S.-O. ANDERSSON et al.
(T2-T4). In all patients the tumour was graded and staged in
accordance with the WHO and UICC classifications, respec-
tively (International Histological Classification, 1980; UICC,
1978). The presence of metastases was assessed by skeletal
scintigraphy. On the basis of the TNM classification, the
patients were classified into one of three mutually exclusive
groups, namely a group with localised (T0-2,NX,MO), locally
advanced (T3-4,NX,MO) or generalised (TO-4,NX,M1) di-
sease.
Male controls were frequency-matched for age (<50,
50-59, 60-69, 70-79) and randomly selected every 3 months
from the county population register. All potential controls
underwent clinical examination by one of the investigators
(S-O. A.) to rule out the presence of a palpable tumour in the
prostate. Persons with a palpable nodule and/or an elevated
level (>10O g 1') of prostate specific antigen (PSA) in the
serum were investigated further by ultrasound-guided biop-
sies before being definitely accepted as a control.
Blood sample from 100 (86% of all eligible) cases and 100
(76% of all invited) controls were drawn - without fasting -
between 08.00-10.00 a.m. and before digital rectal examina-
tion of the prostate was performed. The samples were cen-
trifuged and stored at - 70°C until assayed. For practical
reasons the assays were performed on two occasions (50
cases/50 controls on each occasion). The samples were analy-
sed for luteinising hormone (LH), follicle-stimulating hormone
(FSH), estradiol, testosterone (total and free), androstene-
dione and SHBG. Body mass index (BMI) was calculated as
weight (kg)/height (m)2. Seven of the cases had to be ex-
cluded from the analysis as they had already received treat-
ment before the blood samples were drawn and two controls
proved to have a prostatic cancer and were excluded; hence
93 cases and 98 controls were included in the analysis.
In order to minimise errors due to bias in the analytical
method, the patient samples were analysed in random order
and every second sample, which was also taken in random
order, was a control.
Serum hormone assays
LH in 25 gdI serum (S-LH) was measured with a time-
resolved Sandwich fluoroimmunoassay (Delfia hLH Spec;
Pharmacia-Wallac Oy, Turku, Finland). In this assay two
different mouse monoclonal antibodies were used, directed
against two different sites on the P subunit. One was
immobilised onto the walls of microtiter plates and the other
was in solution and labelled with europium chelate. The
values were expressed in gg1- and a highly purified human
LH (hLH) preparation was used as a standard. One micro-
gram corresponded to 6.6 IU of the Second International
Reference Preparation (2nd IRP) of pituitary FSH/LH (78/
594). The reference range for healthy men was 0.2-1.6jig 1-',
and the minimal detection limit was 0.007jig 1-'. The within-
and between-assay coefficients of variation were 2.6% and
3.5% respectively.
FSH in 25jil serum (S-FSH) was measured with a time-
resolved Sandwich fluoroimmunoassay (Delfia hFSH; Phar-
macia-Wallac Oy, Turku, Finland). Two different mouse
monoclonal antibodies were used. One was directed against
the ,B subunit of hFSH and immobilised onto the walls of
microtiter wells. The other was in solution, labelled with
europium chelate, and specific for the a subunit. The values
were expressed in jig 1` and a highly purified hFSH prepara-
tion was used as a reference standard. One jig corresponded
to 4.7 IU of the 2nd IRP of pituitary FSH/LH (78/594). The
reference range for healthy men was 0.25-2.5 gg 1-1, and the
minimal detection limit was 0.007fig -'. The within- and
between-assay coefficients of variation were 2.5% and 3.6%
respectively.
Estradiol-17P in 25jil serum (S-E2) was measured with a
time-resolved solid-phase fluoroimmunoassay (Delfia Est-
radiol; Pharmacia-Wallac Oy, Turku, Finland), based on
competition between europium-labelled estradiol and sample
estradiol for polyclonal anti-estradiol antibodies (derived
from the rabbit). A second antibody, directed against rabbit
IgG, is immobilised onto the walls of microtiter plates, and
bind the IgG-estradiol complex. The cross-reactivity for es-
trone at an inhibition level of 50% was 1.5%. The reference
range for healthy men was from non-detectable to 150 pmol
1'. The minimal detection limit was about 20 pmol 1-. The
within-assay coefficient of variation was <10% for values
>50pmollI- and about 7% at 150pmolI1.
Testosterone (total) in 50 Il serum (S-T) was measured with
a solid-phase radioimmunoassay (Coat-A-Count Total Testo-
sterone; Diagnostic Products Corporation, Los Angeles,
USA) based on competition between 1251-labelled testosterone
and sample testosterone for polyclonal anti-testosterone anti-
bodies immobilised to the wall of a polypropylene tube. The
cross-reactivity with dihydrotestosterone was less than 5%.
The reference range for healthy men was 10-45nmoll-1,
and the minimal detection limit was 0.07 nmol1-. The with-
in- and between-assay coefficients of variation were 5% and
8% respectively.
Androstenedione in 0.25 gl serum (S-ASD) was measured
with a radioimmunoassay (Androstenedione Radioimmuno-
assay Kit, Amersham International, Amersham, UK) based
on competition between '251-labelled androstenedione and
sample androstenedione for polyclonal anti-androstenedione
antibodies. The separation of free and bound antigen was
achieved by the use of an accelerated double antibody system
followed by centrifugation. The reference range for healthy
men was 2.0-9.3 nmol 1'. The minimal detection limit was
0.15 nmol1-. The within- and between-assay coefficients of
variation were 3% and 7% respectively.
Albumin in 3 glI serum (S-Albumin) was measured with an
automated analysis Hitachi System 717, using bromocresol
green as a reagent. The results were expressed in g11. The
reference range was 36-48 g1, and the between-assay var-
iation was 2%.
SHBG in 0.25 Id serum (S-SHGB) was measured with a
time-resolved Sandwich fluoroimmunoassay (Delfia SHBG;
Pharmacia-Wallac Oy, Turku, Finland). In this assay, the
SHBG was bound to polyclonal rabbit anti-SHGB antibodies
immobilised onto the walls of microtitration strip wells.
Monoclonal mouse anti-SHBG antibodies labelled with euro-
pium chelate was then bound to the SHBG. The reference
range for healthy men was 1.0-9.3 mg 1l. The minimal
detection limit was 0.05mgl1'. The within- and between-
assay coefficients of variation were 3.5% and 6%, respec-
tively.
Free testosterone in serum (S-ft) was calculated by a for-
mula derived from the law of mass action, assuming two
binding systems, T-SHBG and T-albumin (Sodergard et al.,
1982). The fixed values used for the binding affinity constants
for T-SHBG and T-albumin were 5.97 x 10 M-I and
4.06 x 104 M-1, respectively. The values for S-T (total), S-
SHBG and S-albumin were those determined experimentally
in every sample. One microgram of SHBG = 10.75nmol.
One gram of albumin = 15,400 nmol.
Statistical methods
The serum hormone and SHBG levels in cases and controls
were compared by standard t tests. Comparisons after adjust-
ment for age were made by standard multiple regression
analyses. In the analyses of the relation between hormone
level and the risk of developing cancer, the logistic regression
model was used. This model assumes that the logarithm of
the odds of developing prostatic cancer is a linear function of
the explanatory variables (hormone level and age). By con-
sidering the hormone variables in categorised form, nonlinear
effects were also allowed. The model was estimated by the
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of the model, the odds ratios associated with different
variables and categories were computed.
In the analyses of the influence of tumour stage, tumour
grade and age on hormone values, the standard regression
model was used. The estimated parameters of this model
(Table IV) show the difference between a certain category of
an explanatory variable and the reference category of the
variable (these were localised disease, high grade and age
under 70) after adjustment for the effects of other variables.
The same basic model was used in the univariate analyses of
the corresponding variables. This yielded the P values shown
in Table III.
The results are reported with the hormone variables in
logarithmic form. Analyses were also carried out with the
variables in untransformed form. The results of these analy-
ses did not differ greatly from those shown.
Results
The mean age of the 93 prostatic cancer patients (69.7 years)
closely agreed with that of the 98 controls (69.6 years). A
comparison of the patients (cases) and controls with respect
to the serum hormone levels, SHBG and BMI is shown in
Table I. In none of these comparisons did the mean values
show any statistically significant difference between the
groups. The results after age adjustment were almost iden-
tical. A remarkably close agreement was found in particular
for total and free testosterone, but also for the other hor-
mones and for SHBG. The only marked difference was in the
estradiol level, which was about 16% lower in the cases. The
interindividual variations within each group were high for
almost all these analyses, as indicated by the standard devia-
tions. A logistic regression analysis, with adjustment for age,
further confirmed the similarity in mean serum hormone
levels between cases and controls.
Table II shows the age-adjusted odds ratio and 95%
confidence interval. Each hormone was analysed both as a
logarithmic continuous variable and after categorisation into
tertiles based on values in the controls, using the lowest
tertile as a reference group. No statistically significant
difference was found between cases and controls for any of
the hormones or for SHBG (Table II). For testosterone, the
hormone of primary interest, the odds ratio for the highest
compared with the lowest tertile was 0.97, whereas the mean
values of these tertiles differed about 2.4-fold. A similar
magnitude of variation in the serum concentrations and a
similar lack of association with case-control status was noted
for free testosterone. There was some evidence of a decreas-
ing risk with increasing serum levels of estradiol and SHBG,
but the effect was not statistically significant. Similarly,
analyses ofeach hormone and SHBG in continuous form did
not reveal any statistically significant difference between cases
and controls; the P values were 0.29 (estradiol) or higher
(data not shown).
Table I Mean serum concentrations, with standard deviations (SD),
of LH, FSH, total and free testosterone, estradiol, androstenedione,
SHBG, mean BMI with SD and mean age in 93 patients with
prostatic cancer and in 98 population controls
Cases Controls
Factor Mean (SD) Mean (SD) P-valuea
LH (jiGL') 0.917 (0.665) 0.968 (0.832) 0.70
FSH (g I-') 1.777 (1.929) 1.896 (2.234) 0.83
Total testosterone 15.84 (6.75) 15.97 (6.27) 0.59
(nmol 1-')
Free testosterone 0.295 (0.111) 0.293 (0.103) 0.86
(nmol 1-')
Estradiol (pmoll-') 66.2 (41.4) 79.0 (101.4) 0.30
Androstenedione 6.08 (2.24) 5.86 (1.70) 0.67
(nmol 1-1)
SHBG (mg -') 4.86 (2.21) 5.06 (2.46) 0.48
BMI 26.3 (3.2) 25.8 (2.9) 0.09
Age 69.7 69.6
at-test on log values.
Table II Odds ratios (OR), adjusted for age with a 95% confidence
interval (CI) for each factor analysed as a categorised variable
Tertiles
Factor Range Mean OR 95% CI
LH <0.565 0.405 1.00 ref
(mg1-') 0.565-0.945 0.740 0.91 0.45-1.85
>0.945 1.683 0.88 0.43-1.81
FSH <0.865 0.601 1.00 ref
(mgl') 0.865-1.565 1.125 1.57 0.77-3.18
> 1.565 3.720 1.19 0.57-2.47
Testosterone
(nmol I-') total < 12.15 9.77 1.00 ref
12.15-17.60 14.53 1.18 0.58-2.38
>17.60 23.05 0.97 0.49-1.94
free <0.243 0.195 1.00 ref
0.243-0.327 0.281 1.51 0.75-1.11
>0.327 0.407 1.21 0.60-2.42
Estradiol <42.5 25.9 1.00 ref
(pmol 1) 42.5-84.5 64.2 0.85 0.42-1.71
>84.5 127.5 0.61 0.30-1.25
Androstenedione <5.10 4.08 1.00 ref
(nmol l-') 5.10-6.45 5.78 1.06 0.53-2.13
>6.45 8.05 0.88 0.44-1.77
SHBG <3.75 2.97 1.00 ref
(mg1-') 3.75-5.55 4.57 0.90 0.45-1.82
>5.55 7.33 0.76 0.37-1.56
The possibility that serum concentrations of hormones or
SHBG might be associated with the tumour stage, tumour
grade or age was also analysed (Table III). Increasing values
of LH (P = 0.005) and FSH (P = 0.007) with advancing
tumour stage were found. A similar, but nonsignificant,
tendency toward increasing values of LH and FSH with a
decreasing grade of differentiation was also evident. Patients
over the age of 70 years tended to have higher values of LH,
FSH and SHBG than younger patients, and this difference
was statistically significant for FSH (P = 0.02) and SHBG
(P = 0.02). Among the controls also, the LH, FSH and
SHBG values tended to be higher in the over-70 age group
(data not shown). In contrast, the steroid hormone levels
were seemingly unrelated to stage, grade or age of the patient
(Table III).
Thus, only LH, FSH and SHBG showed a statistically
significant relation to tumour stage, tumour grade or age.
These factors were studied simultaneously in multivariate
analyses with each hormone as the dependent variable with
the aim of finding independent determinants of serum con-
centrations and to quantify the strength of the association
(Table IV). Increasing values for LH and FSH with increas-
ing tumour burden were found (P = 0.05 and P<0.05
respectively). The mean logarithmic values for LH and FSH
were 0.50 and 0.69 units respectively, and were higher in
generalised than in localised disease. After adjustment for
tumour stage (and age), no significant association was seen
between tumour grade and LH or FSH. Patients above 70
years of age had slightly higher values of LH, FSH and
SHBG than younger patients; the logarithmic value for
SHBG was 0.21 units higher than in younger patients
(P<0.05).
Discussion
This study was carried out on a consecutive sample of
patients with newly diagnosed prostatic cancer in a strictly
defined population. In contrast to several previous studies
(Harper et al., 1976; Bartsch et al., 1977b; Hammond et al.,
1978; Habib, 1980; Saroff et al., 1980; H0isaeter et al., 1982;
Zumoff et al., 1982; Ranikko & Adlercreutz, 1983; Hulka et
al., 1987), the control group was population-based and pros-
tate cancer was ruled out by digital rectal examination and
serum analysis for prostate-specific antigen. Serum samples
were drawn, stored and analysed according to highly standar-100 S.-O. ANDERSSON et al.
Table III Mean serum concentrations, with standard deviations (SD), of LH, FSH, total and free testosterone, estradiol,
androstenedione and SHBG by tumour stage, tumour grade and age in 93 patients with prostatic cancer
Stage Grade Age
Factor TO-2NXMO T3-4NXMO TO-4NXMI High Medium Low < 70 > 70
LH Mean 0.77 1.02 1.26a 0.87 0.93 1.22 0.79 1.03
(Jig 1-') SD 0.51 0.80 0.71 0.63 0.69 0.81 0.58 0.72
FSH Mean 1.42 2.06 2.53b 1.69 1.77 2.37 1.30 2.20c
(g1g') SD 1.21 2.71 1.76 1.38 2.72 1.96 1.04 2.40
Testosterone Mean 15.4 17.4 13.9 15.3 17.8 12.2 15.1 16.5
(nmol 1-') SD 5.5 8.1 7.3 5.0 9.0 6.5 5.5 7.7
Testosterone, free Mean 0.29 0.32 0.26 0.29 0.33 0.24 0.29 0.30
(nmol -l') SD 0.088 0.141 0.108 0.077 0.151 0.123 0.081 0.133
Estradiol Mean 63.6 73.2 58.8 65.8 65.4 72.3 60.7 71.1
(pmol1-') SD 39.8 42.1 46.9 41.8 41.1 44.6 35.8 45.6
Androstenedione Mean 6.03 6.25 5.88 6.08 6.30 5.28 6.33 5.86
(nmol 1-') SD 2.21 2.38 2.20 1.97 2.85 1.47 2.42 2.07
SHBG Mean 4.70 5.11 4.88 4.75 5.16 4.54 4.44 5.23d
(mg I-') SD 2.36 1.96 2.29 1.77 3.02 1.49 2.45 1.91
ap = 0.005 compared with stage TO-2NXMO. bp = 0.007 compared with stage TO-2NXMO. cP = 0.02 compared with age
<70. SP = 0.02 compared with age <70.
dised routines. Differential misclassification between cases
and controls is therefore unlikely, and we consider the inter-
nal validity of the study as high. Moreover, the numbers of
cases and controls should imply a statistical power that is
higher than in most published investigations (Table V). In
addition, when analyses are based on only one sample, short-
term, intraindividual variations in hormone concentrations
are not large enough to conceal, to any appreciable extent,
any differences that may be present between groups (Dai et
al., 1981).
Our main finding was the absence of an association be-
tween prostatic cancer and pituitary hormones, sex steroid
hormones, or SHBG. Indeed, for most variables the simi-
larity in mean values (Table I) and the lack of a trend after
categorisation into tertiles (Table II) was remarkable. We
noted with special interest that the mean serum concen-
trations of total and free testosterone - the latter the bio-
logically active form - were virtually identical in cases and
controls; and further that a recently reported association
between androstenedione and prostate cancer (Barrett-Con-
nor et al., 1990) was not supported by our data.
The main results in the literature of comparisons regarding
pituitary and sex steroid hormone levels between patients
with prostatic cancer and controls are presented in Table V.
The great disparity in the criteria for selection of controls,
the small numbers of subjects, and the differences in study
Table IV The influence of stage, grade and age on selected
hormone variables in 93 patients with prostatic cancer. Multivariate
analyses. Parameter estimates with standard errors in parentheses.
All hormone variables are given in logarithmic form
Factor LH FSH SHBG
Const - 0.50 0.05 1.38
(0.11) (0.12) (0.09)
T3-4N.M0 0.26 0.33 0.05
(0.16) (0.17) (0.10)
To-4N,M, o.5oa 0.69B - 0.04
(0.25) (0.28) (0.17)
Diff grade Medium - 0.09 -0.42b - 0.03
(0.16) (0.18) (0.11)
Diff grade Low 0.13 - 0.06 - 0.03
(0.28) (0.31) (0.18)
Age >70 0.13 0.27 0.2lb
(0.14) (0.16) (0.09)
R2 0.1103 0.1666 0.0668
ap = 0.051. bp <0.05.
design should be noted. These inconsistencies may partly
explain the varying results.
What conclusions can be drawn from the results of this
study regarding the causal role of hormones in the etiology
of prostatic cancer? Firstly, serum hormone levels as deter-
mined at the time of diagnosis are seemingly not related to
the occurrence of prostatic cancer. However, this does not
preclude the possibility that men who later develop prostatic
cancer may differ in their serum hormone level at younger
ages, when the malignant transformation is initiated, and
that these differences diminish with age. In the United States,
the incidence of and mortality from cancer of the prostate is
substantially higher in blacks than in whites (Greenwald,
1982). Black college students have been reported to have
higher total and free testosterone levels than whites (Ross et
al., 1986).
According to a rival theory, hormones may be important
in the etiology in terms of individual susceptibility at the
cellular level, for example the receptor function or hormone
metabolism may be altered in those who develop prostatic
cancer. In one study an increased production and increased
metabolic clearance rate of testosterone was found even in
patients whose serum testosterone levels did not differ from
those in controls (Meikle et al., 1989). In a recent study the
serum testosterone concentrations in young adult Japanese
men were compared with those in young adult whites and
blacks from the US, but no significant differences were
found. However, the activity of 5-m-reductase was found to
be significantly lower in the Japanese than in the US men
(Ross et al., 1992). These findings suggest that hormone
metabolism may be of importance in the etiology of prostate
cancer. A great disparity between the concentrations of and-
rogens in prostate tissue and serum has also been reported
(Habib, 1980). A third theory is that hormones play a per-
missive role in the etiology of prostatic cancer, but that
variations within the normal range are not associated with
the risk of developing clinical disease. This need not rule out
their importance, however, in the progression, growth and
clinical course of the disease (Ishikawa et al., 1989).
The reason for the higher serum levels of LH and FSH in
patients with more advanced tumours is not clearly under-
stood. These changes may conceivably be secondary to the
(non-significant) decrease in the serum level of testosterone in
patients with more advanced cancer. It is not known, how-
ever, whether a low serum testosterone level is a consequence
or a cause of advanced disease.
In conclusion, this study has shown that at the time of
diagnosis there is no difference in the serum levels of sex
steroid or pituitary hormones or of SHBG between patients
with prostatic cancer and healthy age-matched controls.HORMONES IN THE ETIOLOGY OF PROSTATIC CANCER 101
Table V Main results of case-control and cohort studies with comparisons of serum hormone levels between patients with prostatic
cancer and controls
Results'
Number Typea of Higher No Lower
Author Cases Controls controls in cases difference in cases
Young & Kent, 1968 28 55 C + E T
Habib et al., 1976 10 10 D T,DGT,A
Harper et al., 1976 33 76 B + D T,A,E2,FSH,LH
Bartsch et al., 1977a 29 38 B + E E1,E2,FSH,T DHT,LH
Bartsch et al., 1977b 33 38 E T,DHT,E,,E2,SHBG
Hammond et al., 1978 11 97 D+E T,E2,A
Ghanadian et al., 1979 33 42 E T DHT
Jackson et al., 1980 US black 108 183 B T,El
Nigerians 65 70 El T
Jacobi et al., 1980 73 72 D+ E T,P
Saroff-Kirdani et al., 1980 97 26 D+ E T,DHT
Ahluwalia et al., 1981 US black 170 unknown E T,E, DHT,E2
Nigerians 55 DHT,E2 T
Drafta et al., 1982 32 108 D+E T EI,E2
Hill et al., 1982 21 19 D+E El E2 T,A
H0isaeter et al., 1982 100 E SHBG T,E2,FSH,LH
Meikle et al., 1982 126 54 E E2,SHBG T
Zumoff et al., 1982 16 36 E El LH,FSH,P T
Rannikko et al., 1983 30 50 D + E SHBG T,E2,P TF
Levell et al., 1985 80 71 D TF,T (>75 yrs) TF,T (<65 yrs)
Hulka et al., 1987 35 203 D T,E2
Nomura et al., 1988 98 98 Cohort 6860 males T,DHT,E1,E2,SHBG
Hsing et al., 1989 103 103 A T,DHT,E1,E2,P,FSH,LH
Meikle et al., 1989 38 22 E E2,T,LH,FSH
Barrett-Connor, 1990 57 Cohort 1008 males A T,E1,E2,SHBG
aA = population controls, B = hospital controls, C = patients with other cancers, D = patients with benign prostatic hyperplasia,
E = healthy but not population-based controls. bA = Androstenedione, D = Dihydrotestosterone, El = Estrone, E2 = Estradiol,
SHBG = Sex-hormone-binding globulin, FSH = Follicle-stimulating hormone, LH = Luteinizing hormone, P = Prolactin,
T = Testosterone, TF = Free testosterone.
Future investigations on the possible role of hormones in the
etiology of prostatic cancer should therefore probably be
focused on earlier ages, or on intracellular metabolic changes.
This work was supported by grants from Orebro County Council
Research Committee and The Swedish Cancer Society.
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